Printer Friendly

ALLERGAN HONORED FOR BOTOX(TM) DEVELOPMENT BY NATIONAL ORGANIZATION FOR RARE DISORDERS

 ALLERGAN HONORED FOR BOTOX(TM) DEVELOPMENT
 BY NATIONAL ORGANIZATION FOR RARE DISORDERS
 IRVINE, Calif., May 19 /PRNewswire/ -- Allergan, Inc. (NYSE: AGN) was honored last night by the National Organization for Rare Disorders (NORD) for efforts to ensure access to BOTOX(TM) (botulinum toxin type A) therapy for people suffering from rare muscle disorders. NORD presented Allergan with its 1992 Corporate Leadership Award for outstanding commitment to orphan drug development at a banquet in Washington, D.C.
 BOTOX(TM) (botulinum toxin type A), an orphan drug which has 16 years clinic research experience, is currently marketed by Allergan for treatment of two ocular muscle disorders, blepharospasm and adult strabismus. Though relatively rare, both conditions can be debilitating, and the former often leaves people functionally blind.
 In accepting the award for Allergan, William C. Shepherd, president and chief executive officer, said, "BOTOX(TM) therapy really makes a difference in the lives of people suffering from these rare muscle disorders. This realization and the recognition by NORD makes us very proud and reaffirms our commitment to invest in orphan drug development. We believe that orphan drugs should provide affordable therapy with responsible profits for the providers."
 Allergan currently is awaiting FDA approval to market BOTOX(TM) (botulinum toxin type A) in the United States for cervical dystonia, a condition that causes the head to become immobilized in an abnormal position as a result of neck muscle spasms. Allergan also is sponsoring a number of clinical trials to evaluate BOTOX(TM) (botulinum toxin type A) for other rare muscle disorders such as juvenile cerebral palsy.
 Allergan, Inc., headquartered in Irvine, is a global provider of specialty therapeutic products; is expanding beyond skin care and its leadership position in eye care into adjacent markets; and is pursuing other core technologies.
 -0- 5/19/92
 /CONTACT: Shel Holtz (media), 714-752-4387 (work) or 818-366-5296 (home); or Jeff D'Eliscu (investor relations), 714-752-4636 (work) or 714-675-9475 (home), both of Allergan/
 (AGN) CO: Allergan, Inc. ST: California IN: MTC SU:


KJ -- LA022 -- 2037 05/19/92 16:57 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1992
Words:339
Previous Article:HOWTEK ANNOUNCES OEM AGREEMENT WITH CROSFIELD FOR MAGNASCAN 200i
Next Article:ALLWASTE ANNOUNCES TERMINATION OF NEGOTIATIONS TO ACQUIRE CATALYST HANDLING BUSINESS
Topics:


Related Articles
Researchers Announce Promising Results for the Prevention of Migraine Headaches.
ALLERGAN'S BOTOX GETS FDA APPROVAL FOR CERVICAL DYSTONIA.
ALLERGAN'S BOTOX RECEIVES EU APPROVAL FOR HYPERHIDROSIS (EXCESSIVE SWEATING) IN THE UK.
AMENDMENT TO NEWS RELEASE ON BOTOX IN HYPERHIDROSIS.
BOTOX THERAPY BRINGS QUALITY OF LIFE :: PR Newswire, London, October 11.
BOTOX THERAPY BRINGS QUALITY OF LIFE.
On the road again to Atlanta: communication continues to be key with Allergan's participation in World Congress and Exposition on Disabilities.
Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for...
Video: Allergan, Inc. Marks 20 Years Since the First Approved Indications by the U.S. Food and Drug Administration for BOTOX(R) (Botulinum Toxin Type...
VIDEO: Allergan, Inc. Announces the 'BOTOX(R) Cosmetic: Express Success' Charitable Education Campaign, Committing $250,000 to the Not-For-Profit...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters